Belgian Biotechnology Belgium: Companies by Sector

Belgian Biotechnology Belgium: companies by sector Turnhout Beveren Lommel Oostende Brugge Zelzate Antwerpen Herentals Balen Lokeren Lier Bree Veurne Torhout Gent Boom Heist-op- Westerlo den-Berg Dendermonde Tielt Ieper Wetteren Mechelen Diest Genk Hasselt Asse Leuven Waregem Poperinge Oudenaarde Brussels Ninove Sint-Truiden Ronse Overijse Tienen Geraardsbergen Tongeren Mouscron Wavre Visé Tubize Waterloo Tournai Enghien Waremme Ath Eupen Soignies Nivelles Liège Gembloux Verviers La Louvière Mons Huy Aywaille Namur Malmedy Binche Charleroi Durbuy Ciney Dinant Florennes Vielsalm Marche-en-Famenne Philippeville Agricultural & Food St-Hubert Couvin Gedinne Bastogne Libramont Healthcare Bouillon Industrial & Environmental Arlon Multi-sector Virton Contents Presentation of the sector �� 4 Belgium, a key player in biotechnology in Europe ��6 Well supported: the Belgian players in biotechnology ��8 A leading country for research �� 11 An industry with strengths right along the value chain �� 12 The real challenge: finance �� 13 A fiscal environment designed for foreign investors �� 14 Biotechnology success stories in Belgium �� 16 Health �� 18 Delphi Genetics ��18 ThromboGenics �� 20 Peptisyntha �� 22 IBA Ion Beam Applications ��24 Ovizio �� 26 Cardio3 BioSciences �� 28 Artelis �� 30 Industry and environment ��32 Ecover �� 32 Agriculture and food ��34 CropDesign �� 34 Index of companies �� 36 Agriculture & Food ��38 Healthcare �� 42 Industry & Environment ��60 3 1 Presentation of the sector Belgium, a key player in biotechnology in Europe Share of the world market Research and development The quality of an industry is reflected in part by its export Spending on research and development is high in relation performance� These figures demonstrate the competitive to the country’s size, as confirmed by the latest OECD edge of a country’s products and businesses� figures: Belgium is one of the most open economies in the world, À Fifth-highest level in the OECD of public funding (direct and this is true for the biotechnology sector too� Although and indirect) and tax incentives for R&D in the business the country represents only 3% of the economy of the EU27, sector in 2008� it accounted for 17% of EU exports of biopharmaceuticals in À Fourth country in the world in terms of biotechnology 2008� In 2009, the Belgian trade balance for pharmaceuti- R&D per firm� cals was in large surplus (€7,216,415), and exports grew by 11�76% between 2008 and 2009� À Third country in Europe in terms of biotechnology R&D per capita in the business sector� In addition, Belgium accounts for a remarkably high proportion of Europe’s turnover in biotechnology� It represents À Second highest proportion of biotechnology R&D in total 16% of the European biopharmaceutical industry, making national R&D in the world� our country a key player at world level� À World number one for R&D intensity (R&D / production) in the pharmaceutical industry (EFPIA, 2008)� Relative importance of Belgium in the EU27 in 2008 (biopharmaceuticals) Number of companies 18% The Belgian biotechnology sector is divided into three dis- 17% tinct areas: red, white and green� The country’s main asset 16% 16% is in health-related biotechnology: this accounts for 80% of the national activity� White and green biotechnology are growing rapidly, and account for 15% and 5% respectively 14% of the total� 12% The biotechnology sector is vast and covers a wide range 10% of industries� This study includes companies that meet the sectoral definition used by the OECD: “The application of 8% science and technology to living organisms, as well as parts, 8% 7% products and models thereof, to alter living or non-living mate- 6% rials for the production of knowledge, goods and services”� 6% Based on this definition, 17% of the country’s 308 biotech businesses are concentrated within Brussels itself, while 4% 3% Flanders and Wallonia host 49% and 34% respectively� 2% 2% 0% n e s g r o P u n e ti D l rm i v a G a ﬁ d o l v f n n Belgian workers are among u d o e r p e r p u Exports o d e s T P d b D the five most productive in the A m & u R N world, according to recent figures from OECD and the International Source: EFPIA, Eurostat for the added value, bio.be for the number of firms and turnover Labour Organisation (2008)� But it is particularly in the biotechnology sector that Belgian superiority is most striking� 6 7 Innovation Employment Belgian biotechnology provides direct employment to more sector Revealed biotechnological advantage (2004-06) than 30,000 people in Belgium, mainly in the health sector (80%)� These workers are particularly well qualified, and train- the Denmark ing in science and technology in Belgium is among the best Belgium in Europe, both at secondary level and in universities� Belgian workers are among the most productive in Europe� Singapore Canada New Zealand Some of the most productive researchers in the world Presentation of Australia Poland 1. Belgian workers are among the top 5 most productive in the Spain world according to recent OECD statistics and the International Labour Organisation� But it is especially in the biotechnology United States sector that the country stands out: Israel À In Belgium the number of drugs in development per mil- 0 0.5 1.0 1.5 2.0 2.5 lion inhabitants is the highest in the world, ahead of the United Kingdom or the United States� Source : OECD, 2009 À The regions of Flemish Brabant and Walloon Brabant have respectively 61% and 58% of scientists in their economically The Belgian innovation system is among the best in the world� active population, placing them in the top 10 European According to the latest figures from OECD, our country has regions in this regard� the fourth largest global technological advantage in biotechnology, and the third in Europe� OECD describes Belgium’s strengths as: À The number of active researchers in the pharmaceutical industry in Belgium is growing rapidly� Between 2002 and 2007, it rose from 3,591 FTEs to 4,838, an increase À the importance that public authorities give to the sector; of 35%� À the strong concentration of researchers in the workforce; À Belgium consistently outperforms the OECD average, in À the high number of graduates in science and engineering; terms of researchers per thousand employees, the number of science and engineering graduates as a percentage À the share of science and technology employment in total of degrees awarded, the proportion of employment in employment; science and technology in total employment, or scientific articles published per million population (OECD, 2010)� Its th À strong collaborative relationships in innovation; human resources also help make Belgium the 6 most innovative member of the EU27� À and a remarkable degree of openness in the sector to Foreign investors have seized the opportunities, and we are one international partnerships (the leading OECD country in of the world’s most open countries to international research� terms of the percentage of national inventions owned by 50% of Belgian inventions are owned by foreigners, against foreigners, and 59% of R&D in the country is conducted an OECD average of just 15%� Belgians work closely with by foreign affiliates)� foreign researchers, and are integrated into major international networks to provide research of the highest quality� In Belgium the number of drugs in development per million inhabitants is the highest in the world, ahead of the United Kingdom or the United States� Patrik De Haes, CEO ThromboGenics 6 7 Well supported: the Belgian players in biotechnology 1. SupporT And ADVice TO ForeiGN inVesTors FIT, AWEX and Brussels Export each promote 1. Supporting exporters from the region their own region: Flanders, Wallonia and Brussels� 2� Informing, prospecting for, and advising potential They have three main tasks that they each fulfill in foreign investors their own way: 3� Promoting the region abroad nanotechnology sectors can provide US companies with specific information on biotechnology in Flanders� There are great advantages in having an attaché who is fully informed about the sector, who can build a professional network,

Load more